Clinical Trials Logo

Filter by:
NCT ID: NCT03364036 Completed - Multiple Sclerosis Clinical Trials

Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

Start date: May 28, 2018
Phase: Phase 4
Study type: Interventional

The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).

NCT ID: NCT03363984 Completed - Healthy Clinical Trials

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Start date: November 27, 2017
Phase: Phase 1
Study type: Interventional

A clinical study in healthy male subjects to investigate whether the administration of ID-082 can affect the fate in the body (amount and time of presence in the blood) of midazolam.

NCT ID: NCT03363893 Completed - Clinical trials for Advanced Solid Malignancies

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Start date: November 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

NCT ID: NCT03363854 Completed - Atopic Dermatitis Clinical Trials

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Start date: February 22, 2018
Phase: Phase 3
Study type: Interventional

Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared with placebo in combination with TCS. To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 32 weeks.

NCT ID: NCT03362931 Completed - Glaucoma Clinical Trials

Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma

Start date: July 19, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.

NCT ID: NCT03362437 Completed - Thrombosis Clinical Trials

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Start date: November 15, 2017
Phase: Phase 1
Study type: Interventional

Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B

NCT ID: NCT03362229 Completed - Clinical trials for Ankle Fracture - Medial Malleolus

Medial Malleolus: Operative Or Non-operative

MOON
Start date: October 24, 2017
Phase: N/A
Study type: Interventional

Medial malleolus: Operative Or Non-operative (MOON study) Ankle fractures are a common Orthopaedic trauma presentation, accounting for approximately 10% of the workload. There has been debate regarding the significance of the contribution of the medial malleolus to ankle stability. Some deem the lateral malleolus as the key stabiliser. With this anatomically aligned the ankle joint should be stable. Operating on the medial malleolus fracture often requires a second generous skin incision, soft tissue stripping and insertion of metalwork. This carries with it the risk of wound complications, infection and increased operation time. High risk patients including the elderly, diabetics and those with significant swelling following injury are particularly vulnerable. The study will include adult patients (≥16 years) with capacity to consent and complete post-operative questionnaires, presenting to a single Orthopaedic trauma unit. Participants will be randomised to fixation or non-fixation of associated medial malleolus fractures at the same time as fixation of the lateral malleolar fracture to assess if this impacts on validated patient outcomes, failure, operative time and complications over a one-year follow-up. Only one trial has been published, showing no significant difference between failure rates or outcomes, but reduced operative time. Participants will be enrolled into the trial following informed consent. The final decision on whether a participant is eligible can only be made during surgery when the medial malleolus fracture has reduced with no more than 2mm displacement. If this is confirmed the participant will be randomised to receive either fixation or non-fixation of the medial malleolus. Randomisation therefore occurs at the time of surgery. Participants will be reviewed at set post-operative checkpoints, with X-rays and patient reported outcome scores. Trial data will hopefully enable surgeons to make better informed decisions when managing patients with ankle fracture dislocations.

NCT ID: NCT03361956 Completed - Hepatitis B Clinical Trials

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Start date: February 13, 2018
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.

NCT ID: NCT03361865 Completed - Clinical trials for UC (Urothelial Cancer)

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.

NCT ID: NCT03360812 Completed - Terminal Illness Clinical Trials

ORaClES: A Trial to Improve Prognostication

ORaClES
Start date: April 5, 2018
Phase: N/A
Study type: Interventional

This study evaluates whether an online training resource can improve the performance of medical students in recognising imminently dying palliative care patients.